Want to see INDP full AI Analyst Report?
Indaptus Therapeutics (INDP) Stock Statistics & Valuation Metrics
Total Valuation
Indaptus Therapeutics has a market cap or net worth of $497.60M. The enterprise value is $336.84M.
- Market Cap
- $497.60M
- Enterprise Value
- $336.84M
Share Statistics
Indaptus Therapeutics has 153,581,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 153,581,300
- Owned by Insiders
- 0.28%
- Owned by Institutions
- 0.17%
Financial Efficiency
Indaptus Therapeutics’s return on equity (ROE) is -6.62 and return on invested capital (ROIC) is -629.32%.
- Return on Equity (ROE)
- -6.62
- Return on Assets (ROA)
- -2.24
- Return on Invested Capital (ROIC)
- -629.32%
- Return on Capital Employed (ROCE)
- -6.29
- Revenue Per Employee
- 0
- Profits Per Employee
- -4.17M
- Employee Count
- 5
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Indaptus Therapeutics is -0.47. Indaptus Therapeutics’s PEG ratio is -0.00.
- PE Ratio
- -0.47
- PS Ratio
- 0.00
- PB Ratio
- 33.70
- Price to FCF
- -24.61
- Price to Operating Cash Flow
- -25.24
- PEG Ratio
- -0.00
Income Statement
In the last 12 months, Indaptus Therapeutics had revenue of 0 and earned -20.85M in profits. Earnings per share was -21.58.
- Revenue
- 0
- Gross Profit
- 0
- Operating Income
- -19.83M
- Pretax Income
- -20.85M
- Net Income
- -20.85M
- EBITDA
- -20.85M
- Earnings Per Share (EPS)
- -21.58
Cash Flow
In the last 12 months, operating cash flow was -15.18M and capital expenditures 3, giving a free cash flow of -15.18M billion.
- Operating Cash Flow
- -15.18M
- Free Cash Flow
- -15.18M
- Free Cash Flow per Share
- -0.13
Dividends & Yields
Indaptus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -4.08%
- Earnings Yield
- -4.04%
Stock Price Statistics
- Beta
- 1.19
- 52-Week Price Change
- 16.20%
- 50-Day Moving Average
- 2.59
- 200-Day Moving Average
- 2.27
- Relative Strength Index (RSI)
- 55.31
- Average Volume (3m)
- 909.41K
Important Dates
Indaptus Therapeutics upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 13, 2026
- Next Earnings Date
- Nov 17, 2026
- Ex-Dividend Date
- ―
Financial Position
Indaptus Therapeutics as a current ratio of 1.51, with Debt / Equity ratio of 0.00%
- Current Ratio
- 1.51
- Quick Ratio
- 1.51
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.41
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Indaptus Therapeutics has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Indaptus Therapeutics EV to EBITDA ratio is -23.59, with an EV/FCF ratio of -24.00.
- EV to Sales
- 0.00
- EV to EBITDA
- -23.59
- EV to Free Cash Flow
- -24.00
- EV to Operating Cash Flow
- -24.00
Balance Sheet
Indaptus Therapeutics has $11.55M in cash and marketable securities with $0.00 in debt, giving a net cash position of $11.55M billion.
- Cash & Marketable Securities
- $11.55M
- Total Debt
- $0.00
- Net Cash
- $11.55M
- Net Cash Per Share
- $0.08
- Tangible Book Value Per Share
- $0.10
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Indaptus Therapeutics is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- 81.43%
Scores
- Smart Score
- 3
- AI Score
- 51
